Patent ID: 9133515
Filing Date: 2015-09-15
Classification: A61P,C12N,C12Q,G01N

Abstract:
1. A method of treating a subject and determining the responsiveness of the subject to treatment with a protein kinase N beta (PKN3) inhibitor comprising: determining the level of a VEGFR1 or of a nucleic acid coding for a VEGFR1 in a sample from the subject prior to the treatment of said subject, administering a PKN3 inhibitor to said subject having a disease treatable with said PKN3 inhibitor; determining the level of a VEGFR1 or of a nucleic acid coding for a VEGFR1 in a sample from the subject after the subject has been subjected to the method of treatment; and identifying the subject as a responder to said treatment with said PKN3 inhibitor if the level of a VEGFR1 or a nucleic acid coding for a VEGFR1 in a sample from the subject after the subject having been subjected to the method of treatment is decreased compared to the level of a VEGFR1 or a nucleic acid coding for a VEGFR1 in a sample from the subject prior to the subject having being subjected to the method of treatment; and administering said PKN3 inhibitor to a subject identified as a responder to said treatment.